MSH6 Knockout Cell Line (HEK293)

The choice depends on whether you are studying MSH6's role as the principal MutSα partner of MSH2 for base-base mismatch recognition or modeling Lynch syndrome (HNPCC) and constitutional MMR deficiency (CMMRD). The Knockout line is the standard tool for asking whether MSH6 is required for these activities — MSH6 partners with MSH2 to form MutSα, which recognizes single-base mismatches and small insertion-deletion loops (1-2 nt), making it the principal MutS complex for base-substitution MMR. Overexpression is useful for studying MSH6 in heterologous expression contexts or for testing disease-associated mutations. For mismatch repair research, the EDITGENE MSH6 Knockout in HEK293 is a workhorse mechanistic platform — HEK293 supports systematic MMR biochemistry and structure-function studies. This product complements the parallel MSH6 Knockout in HAP1 (also available); HEK293 is preferred for biochemistry, HAP1 for clean loss-of-function studies. MSH6 mutations cause Lynch syndrome and biallelic MSH6 loss causes CMMRD. Rescue with wild-type or ATP-binding-deficient MSH6 enables structure-function studies. The knockout is valuable for studying MSI-high cancer immunotherapy response (pembrolizumab is approved for MMR-deficient cancers regardless of tissue of origin).

Primary applications: • Mismatch repair activity: in vitro MMR reconstitution assays using HEK293 nuclear extracts and defined heteroduplex substrates. • Microsatellite instability: BAT-25, BAT-26, MONO-27 mononucleotide repeat tract stability analysis. • Lynch syndrome modeling: rescue with patient-derived MSH6 mutations for genotype-function studies. • Chemotherapy sensitivity: 6-thioguanine (purine analog), MNNG (methylating agent), and platinum-based chemotherapy dose-response analysis. EDITGENE recommends this HEK293-based model for biochemical MMR research; the parallel MSH6 Knockout in HAP1 is preferred for unbiased phenotypic screens.

Yes. MSH6 rescue experiments are well-established for MMR research: • Construct design: use a codon-modified MSH6 sequence with a small C-terminal tag (FLAG, HA). MSH6 has N-terminal PWWP domain (chromatin reader), central MutS-like domain, and C-terminal ATPase domain — preserve all elements. • ATPase-deficient rescue: K1140A mutation in the ATP-binding lysine abolishes MMR activity and is the standard specificity control. • MSH2 partnership: MSH6 requires MSH2 for stability and MutSα formation — rescue interpretation considers MSH2 expression. • Lynch syndrome mutation rescue: patient-derived MSH6 mutations enable disease genotype-function studies. • Functional readout: rescue should restore MMR activity, microsatellite stability, and 6-thioguanine sensitivity. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.